Trial Profile
A Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase II Study to Assess the Efficacy and Safety of 100IR, 300IR and 500IR Sublingual Tablets of House Dust Mite Allergen for the Treatment of Allergic Rhinitis in an Environmental Exposure Chamber Model
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2017
Price :
$35
*
At a glance
- Drugs S 524101 (Primary)
- Indications Perennial allergic rhinitis
- Focus Therapeutic Use
- Sponsors Stallergenes SA
- 06 May 2016 Results published in the Journal of Allergy and Clinical Immunology
- 07 Mar 2016 Results from this and other trial (Clinical trial profile-44884) presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 05 Mar 2016 Results presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2016 Annual Meeting, according to a Stallergenes BV media release.